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a b s t r a c t
Hepatosplenic T cell lymphoma (HSTCL) is a type of hematologic neoplasia with a poor prognosis and a
high frequency of refractoriness to conventional chemotherapy. The results obtained by high dose
chemotherapy followed by autologous stem cells transplantation seem to be a more effective option but
still unsatisfactory. Also the role of allogeneic stem cell transplantation is still unclear, although the few
cases reported on the literature would seem to show good results in overall survival rates.
In this paper, we reported the patient's medical history affected by a αβ variant of hepatosplenic T cell
successfully rescued with a haploidentical transplant.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Hepatosplenic T cell lymphoma (HSTCL) is a very rare type of
hematologic malignancy, making up about 5% of peripheral T-cell
lymphomas. It predominantly affects young male adults, with a
higher incidence in patients submitted to immunosuppressive
treatment for chronic inﬂammatory bowel disease. This unfre-
quent lymphoma is characterized by extranodal inﬁltration of
mature malignant post-thymic T-lymphocytes into sinusoids of
the liver and spleen, so it usually presents with hepatosplenome-
galy (without lymphadenopathy) and the presence of peripheral
blood cytopenia, which reﬂects a high incidence of bone marrow
inﬁltration [1].
Two subtypes of HSTCL are described in the last World Health
Organization (WHO) classiﬁcation: a more common form expres-
sing γδ T-cell receptor (TCR) chain and a rarer second one
expressing αβ TCR chain. Both present similar onset and clinical
course and the αβ subtype of HSTCL is considered an immuno-
phenotypic variant.
HSTCL is a highly aggressive malignancy associated with a poor
prognosis, because the results obtained by conventional che-
motherapy usually are disappointing, with a median overall
survival barely exceeding 1 year [2]. Given the rarity and the
aggressiveness of the disease, several investigators have explored
the use of high dose chemotherapy supported by autologous stem
cell transplantation (SCT), without drawing any deﬁnite conclu-
sions [3,4].
Allogeneic SCT (BMT) has a well established role in the
treatment of otherwise incurable malignancies; in relapsed or
refractory peripheral T-cell lymphoma, alloSCT enables to achieve
a long-term remission in nearly 40% of the patients [5].
In patients affected by HSTCL there are anedoctal reports and
small case series reporting beneﬁcial effect of the allografting
procedure, using HLA identical sibling or matched unrelated
donors (MUD) [6–8].
In this report we describe, probably, the ﬁrst case of refractory
HSTCL to a previous autologous SCT and successfully rescued by a
haploidentical allogeneic stem cell transplant (Haploidentical-SCT).
2. Case report
A 48-year-old man, without any relevant past medical pro-
blems and no social/physiological abnormalities, was referred to
our service in May 2012 with fever, fatigue, weight loss, sweating
and abdominal pain. He showed a considerable hepatomegaly
(extending for 8 cm below the right costal margin) and
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splenomegaly (extending for 14 cm below the left costal margin).
Laboratory data showed: haemoglobin level 11 g/dL, platelet count
72109/L, white blood cell count 3.5109/L with neutropenia
(0.96109/L) without morphological abnormalities; AST 184 IU/L and
ALT 128 IU/L (normal values 10–40 IU/l); Lactate-dehydrogenase
4390 IU/L (normalo500 IU/L). Serologic test for toxoplasmosis, cyto-
megalovirus, EBV, HIV, hepatitis, herpesvirus were negative.
Bone marrow analysis revealed the presence of 15% of cells
with morphological aspect of medium-size lymphocytes with
agranular cytoplasm and irregular shaped nuclei with nucleoli.
The ﬂow cytometric immunophenotyping analysis of the bone
marrow cells was positive for CD3 bright, TCR alpha-beta, CD2,
CD16, CD56 and negative for CD4, CD8, CD5 and CD20.
TCR gene arrangement was studied by PCR analysis on marrow
sample and showed clonal restriction of αβ chain [9]. Cytogenetic
analysis revealed a normal karyotype.
A liver biopsy depicted an abnormal lymphocytic inﬁltrate CD3
positive, CD 4 and CD 8 negative and with the same TCR αβ clonal
restriction pattern (Fig. 1).
A computed tomography (CT) was made for completing the
work-up and showed enlarged liver and a massive splenomegaly
with compressive picture on the stomach and with stenosis of
splenic vein and dislocation of the kidney. Cerebrospinal ﬂuid
analysis was negative. All these ﬁndings were diagnostic of
hepatosplenic αβ T cell lymphoma, stage IV B.
The patient was started on induction chemotherapy containing
cyclophosphamide, vincristine, etoposide, doxorubicin and pre-
dnisone (CHOEP) plus central nervous (CNS) prophylaxis with
methotrexate and steroid. After the ﬁrst cycle the patient's clinical
picture did not improved, with persisting hepato-splenomegaly
and liver dysfunction; therefore, we decided to intensify the
treatment protocol with the Hyper-C-HIDAM regimen (cyclopho-
sphamide 300 mg/m2 days 1–3 plus high-dose cytarabine 2 g/m2
bid days 1–3 and methotrexate 2000 mg/m2 for 24 h of continuous
infusion). After three courses a partial remission (PR) was
achieved, with reduction of spleen size but persistence of neo-
plastic marrow involvement. During the fourth course of Hyper-C-
HIDAM the patient was submitted to peripheral blood stem cell
(PBSC) mobilization, with a yield of 6.8106/kg. In October 2012,
a high-dose conditioning therapy (FEAM) was begun with fote-
mustine (150 mg/m2 7, 6), etoposide (100 mg2/m2 5, 4,
3, 2), cytarabine (200 mg2/m2 5, 4, 3, 2) and melpha-
lan (140 mg/m2 1), followed by reinfusion of autologous PBSC
(3.40 CD34þ cells106/kg).
On day 30 after autoSCT the patient underwent a clinical and
laboratoristic restaging: while total body positron emission tomo-
graphy (PET) pointed out a complete response with the normal-
ization of the hepato-splenomegaly, the bone marrow aspirate
revealed the persistence of an abnormal lymphoid population with
the same immunophenotypic proﬁle (7% of cells).
Considering the disease persistence, a decision was made to
perform an allogeneic stem cells transplant with a non myeloab-
tive conditioning (NMA). Since the patient had neither sibling nor
voluntary donors it was established to carry out a HLA-
haploidentical SCT from his daughter. Unfortunately, just a week
before starting the preparative regimen, lymphoma progressed
with an increasing splenomegaly, worsening of pancytopenia and
increasing of the pathologic lymphoid cells in the marrow (70% of
cells). Having evidence of the lymphoma's refractoriness and
considering the patient's young age we re-scheduled our initial
program towards a myeloablative conditioning regimen contain-
ing thiotepa (5 mg/kg 6, 5 days), Busulphan (3.2 mg/kg 5,
4, 3 days) and Fludarabine (30 mg/m2 7, 6, 5, 4 days),
with reinfusion of 2.66106/kg of CD 34þ bone marrow
stem cells.
Fig. 1. Liver biopsy demonstrating a monomorphic, mostly intrasinusoidal, lym-
phoid inﬁltrate (arrow) composed of small to medium size cells (H&E stain, 500 ).
Fig. 2. PCR analysis of TCRβ gene rearrangement using BIOMED-2 protocol. Genescan clonality proﬁles of bone marrow aspirates at diagnosis (A) and after allogeneic stem
cells transplantation (B). Clonal products (arrows) at diagnosis are no more visible at follow up after allogeneic transplantion and a different oligoclonal pattern emerge.
G. Catania et al. / Leukemia Research Reports 3 (2014) 90–93 91
Graft versus host disease prophylaxis included tacrolimus,
mycophenolate mofetil and post transplant cyclophosfamide
(50 mg/kg on days þ3 and þ4) as previously proposed by
Baltimora's group.
Engraftment post SCT was achieved successfully with complete
recovery of hematologic blood count cells at day þ18. Chimerism
evaluation at day þ28 revealed full donor chimerism, which was
conﬁrmed also at days þ60 and þ90, with contemporary demon-
stration of immunophenotipic complete remission at bone mar-
row aspirate. Patient did not show any sign of acute graft versus
host disease (GVDH). The only one acute complication was an
episode of hemorrhagic cystitis secondary to BK virus reactivation,
successfully treated with cidofovir. Six months after transplant,
during tapering of immunosuppression, limited chronic GVHD of
skin and eyes developed, requiring a brief course of steroid plus
UV-B applications; calcineurin inhibitors were substituted with
low dose rapamycin.
After a follow up of 18 months patient is in good clinical
conditions, in persisting complete remission as established both by
PET and CT scan. Moreover the TCR αβ molecular analysis shows
an oligoclonal pattern fully distinct from which manifested during
the disease (Fig. 2).
3. Discussion
In this paper, we report the experience on a patient affected by
a αβ variant of hepatosplenic T cell lymphoma, with rapid
progression after autologous stem cell transplant and successfully
rescued with a haploidentical transplant. Some important con-
siderations might come up from our report.
First, the clinical course of the disease conﬁrmed the dismal
outcome of this subtype of lymphoma with conventional
chemotherapy.
We started with a CHOP regimen but after the ﬁrst cycle we
had to shift the therapeutic approach towards a salvage regimen.
We administered four cycles of hyper-C-HiDAM protocol, a ther-
apeutic scheme containing hyperfractionated cyclophosphamide
plus high-doses of Ara-C and methotrexate [10] followed by
autoSCT. This approach is reported being effective for patients
with aggressive NHL refractory to ﬁrst-line anthracycline-contain-
ing regimens. A partial remission was obtained at the end of the
program. However, as previously reported in PTCL [11,12], only the
achievement of complete remission after induction therapy is a
strong predictor of long term survival; thus, in this category of
patients with a high risk of disease recurrence the general
recommendation is to proceed rapidly to an allogeneic transplant.
Unfortunately the major problem is related to the aggressiveness
of the underlying disease, that does not allow to have enough time
to ﬁnd a suitable donor and to proceed to transplantation.
Considering the disease's aggressiveness and the lack of related
or unrelated full match HLA donor; we decided to proceed anyway
using the haploidentical daughter, despite the very few cases
reported on the literature about the haplo transplants in this
particular subtype of lymphoma.
Historically, alloSCT from HLA-haploidentical relatives has been
limited by an unacceptably high non-relapse mortality, due to high
rates of graft rejection and GVHD [13].
T-cell depletion of the donor graft represented a step forward
in the haplo setting, but it required a high level of expertise in
laboratory techniques [14].
Recently, the Baltimora and Seattle groups have pioneered a
method to selectively deplete alloreactive cells in vivo by admin-
istering high doses of cyclophosphamide immediately post haplo-
transplant (PT/Cy) after a nonmyeloablative conditioning regimen.
This approach resulted in a very low NRM, due to low incidences
of GVHD and infectious complications [15]. In the previous years
several studies [16–18] have conﬁrmed the encouraging results of
the haploidentical PT/Cy strategy. This alternative source with
haploidentical donor is growing as a valid alternative option if a
matched related donor is not rapidly available.
At the beginning our strategy was to follow the Baltimora's original
scheme; however, given the very fast disease progression, we decided
to change the type of pre-transplant conditioning therapy. We chose a
myeloablative regimen with Thiotepa, Bufulsano and Fludarabine, in
an attempt to achieve a better disease control in a patient with a well
established refractory malignancy [19].
Allogeneic transplantation with myeloablative conditioning in
peripheral T-cell lymphoma is a potentially curative option [20],
but it is associated with a high treatment-related mortality (TRM),
in particular after a failed autoSCT [21].Our patient at the time of
transplant was in a relatively young age, in good clinical condi-
tions, and without signiﬁcative comorbidities (Sorror score 0),
despite disease progression and previous treatment.
For that reason, our primary objective was to provide maximal
tumor cytoreduction using a myeloablative preparation regimen
containing high doses of Thiotepa and Busulphan in order to
obtain a better disease control. The efﬁcacy of this treatment was
proved by the demonstration of complete remission at the day
þ60 (no spleen and liver activity on PET scan and the absence of
marrow monoclonal inﬁltrate).
Finally, as previously reported [22] in other subtypes of
peripheral T cell lymphomas, the persistence of complete remis-
sion after allografting corroborates the perception that a graft-
versus-T cell lymphoma effect may play a role in the curative
potential of alloSCT.
Focusing on the clinical history of the patient, we observed a
rapid disease progression few weeks after conventional che-
motherapy and also after autologous transplant; on the contrary
we did not reveal any sign of any molecular relapse after more
than one year of follow-up post haploidentical transplant, as
demonstrated by the oligoclonal TCR pattern.
In conclusion, this report conﬁrms that management of HSTCL
refractory to conventional chemotherapy is still challenging. Some
evidence suggested that haploidentical-SCT can activate an effec-
tive graft-versus lymphoma also in chemoresistant disease. This
approach could offer a valid and safety alternative strategy in
patients with neither a HLA-matched sibling or unrelated donor.
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